NYSE:HQL (USA)
Tekla Life Sciences Investors $ 20.89 -0.11 (-0.52%)
Volume:
108,908
Avg Vol (1m):
79,986
Market Cap $:
498.92 Mil
Enterprise Value $:
498.92 Mil
PE Ratio:
4.07
PB Ratio:
1.03
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Equity-to-Asset | 1 | ||
| Piotroski F-Score | 5 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Net Margin % | 99.17 | ||
| ROE % | 29.1 | ||
| ROA % | 28.99 | ||
| 3-Year Revenue Growth Rate | 16.8 | ||
| 3-Year EPS without NRI Growth Rate | 17.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 4.07 | ||
| PE Ratio without NRI | 4.07 | ||
| PB Ratio | 1.03 | ||
| PS Ratio | 4.03 | ||
| EV-to-Revenue | 4.02 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Dividend Yield % | 7.56 | ||
| Dividend Payout Ratio | 0.28 | ||
| 3-Year Dividend Growth Rate | -2.6 | ||
| Forward Dividend Yield % | 8.23 | ||
| 5-Year Yield-on-Cost % | 7.56 | ||
| 3-Year Average Share Buyback Ratio | -3.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.03 | ||
| Price-to-Graham-Number | 0.43 |